نمایش مختصر رکورد

dc.date.accessioned1399-07-08T17:51:42Zfa_IR
dc.date.accessioned2020-09-29T17:51:42Z
dc.date.available1399-07-08T17:51:42Zfa_IR
dc.date.available2020-09-29T17:51:42Z
dc.date.issued2002-03-01en_US
dc.date.issued1380-12-10fa_IR
dc.identifier.citation(2002). Social Responsibility in Cancer Prevention Research: IARC as a 'Global Science Force'. Asian Pacific Journal of Cancer Prevention, 3(3), 267-272.en_US
dc.identifier.issn1513-7368
dc.identifier.issn2476-762X
dc.identifier.urihttp://journal.waocp.org/article_24134.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/30827
dc.description.abstractTen million new cancer patients are diagnosed each year worldwide. Many specific causes of cancer are known, ‍ranging from factors related to lifestyle, diet and chronic infections to occupational exposures. Primary and secondary ‍prevention continue to be of major importance in cancer control globally. The global burden of cancer, especially the ‍part attributable to infectious diseases, disproportionally affects populations in developing countries. Inadequate ‍access to treatment (pharmaceuticals and other modern technology) plays a role in perpetuating this disparity. ‍Drugs and vaccines may not be accessible because of excessive cost or because development of the required products ‍has been neglected. The remarkable advances in molecular understanding of the carcinogenesis process over the ‍past 25 years have transformed the approaches to cancer control. Promising new tools in preventive oncology, such ‍as immunization (vaccines) and chemoprevention, have emerged. Vaccines are currently being tested in trials e.g., ‍against hepatitis B virus and human papillomaviruses. Chemoprevention has been successfully achieved in animal ‍experiments, and has been validated in several clinical trials. The current agents and strategies should not be ‍regarded as a panacea; more effective and safer vaccines and chemopreventive agents are needed. Future enhanced ‍efforts on an international basis are needed to coordinate the prevention and intervention research efforts in a costefficient ‍and affordable manner. Cancer prevention deserves continuing high priority in terms of both research and ‍application, also in the developing countries. New ventures may be built on possible expansion of IARC’s role in ‍prevention and intervention research into a “Global Science Force” by following the examples of e.g., the Gambia ‍Hepatitis Intervention Study and the cervix cancer screening trials in India. WHO’s support with its regional offices ‍would be beneficial, together with further national funding and support, and research collaboration and funding ‍from more wealthy countries.en_US
dc.format.extent39
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherWest Asia Organization for Cancer Prevention (WAOCP)en_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.subjectGlobal cancer burdenen_US
dc.subjectCancer Preventionen_US
dc.subjectpreventive oncologyen_US
dc.subjectGenomicsen_US
dc.subjectChemopreventionen_US
dc.subjectEarly Diagnosisen_US
dc.subjectScreeningen_US
dc.subjectVaccinationsen_US
dc.subjectHepatitis B Virusen_US
dc.subjectsmokingen_US
dc.subjectsunlight and skin canceren_US
dc.subjectasbestos and mesotheliomaen_US
dc.subjectcervix canceren_US
dc.subjectpapillomaviruseen_US
dc.titleSocial Responsibility in Cancer Prevention Research: IARC as a 'Global Science Force'en_US
dc.typeTexten_US
dc.citation.volume3
dc.citation.issue3
dc.citation.spage267
dc.citation.epage272


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد